India: Product Of Nature: Patentability Issues

Last Updated: 14 July 2019
Article by DPS Parmar

Indian position about patent eligibility of the product of nature still remains in the realms of elusive debates for want any judicial precedence on the subject in India. Section 2 (1) (j) defines that invention means any new product or new process without differentiating between ‘product of nature’ or ‘man made products’. However, Section 3(c) clearly point out that discovery of living things or non- living substances are not patentable inventions. In second limb word ‘mere’ conspicuously is omitted to perhaps leave a room for invention relating to substances occurring in nature which are not discovered but extracted or removed from the nature not occurring freely in nature. Here structure similarity of the pure form with natural form at times creates patentability hurdle of being new as compared to naturally existing one. Its usefulness however, can make it cross the patentability line. There is not inherent stigma or bias on patentability on materials derived or obtained from nature. Patent Law clearly distinguish between finding new substances in nature and making material existing in nature available in a useable form.

Pure vs Impure

The earliest such material that was subject matter of dispute in US was ‘Prostaglandins’ [US 3,069,322] which has wide variety of application in physiological process because of its inherent similar nature like hormones. The claim in this case was for compounds sufficiently pure to give an ideal curve on partition chromatography. The Patent Office Board of Appeals affirming the examiner's rejection of such claims for ‘PGE Type Compounds’ lacking in novelty [as the claimed compounds are naturally occurring] did not find favour with U.S. Court of Customs and Patent Appeals (CCPA) [427 F.2d 1394 (C.C.P.A. 1970)]. According to CCPA “Failing to find pure PGE2and PGE3described in the Bergstrom publication, the board in turn seems to have premised its decision on the inherency of animpureform of PGE2and PGE3in products resulting from certain procedures”, without even looking at “whether theclaimedpure materials arenovelas compared with theless purematerials of the reference.”CCPA observed that “It seems to us that the answer to that question is self-evident: by definition a pure materials necessarily differ fromlesspure or impure materials and, if the latter are the only ones existing and available as a standard of reference, as seems to be the situation here, perforce the "pure" materials are "new" with respect to them.” Webster's New International Dictionary, also defines "pure" as "Separate from all heterogeneous or extraneous matter; free from mixture or combination and "Impure" is defined as "not pure; *****mixed or impregnated with something extraneous * * *." It makes a clear distinction between the two for the purpose of novelty. As the pure material per se did not exist in nature the pure material so obtained was considered sufficiently new to cross the line of novelty. In plain words the novelty is not destroyed when the substance of nature is produced in pure or more useful form. Mostly such patents include claims for isolation and purification as well. However, where patent is granted for product it is limited to the isolated and purified form only not for the form occurring in the nature.

New form of known substance

The question before the examiner today is how to distinguish ‘product of nature’ from ‘products derived from nature’. First he must shed the inherency bias to arrive at the decision on novelty as every such product of nature is not exiting in free state and in useful form. In Indian context mere discovery of new form of known substance if it is a product of nature hit another hurdle of section 3 (d). The question which is required to be answered here is whether the new form of a known substance results in the enhancement of the known efficacy of that substance. If we apply explanation particularly to the ‘pure form’ the applicant is expected to give clear and convincing evidence in terms of difference significantly in properties with regard to efficacy. The difference in form may cross the line of novelty but its improvement in efficacy only can beat the threshold of patentability under section 3 (d). Supreme court view on efficacy is loud and clear that “The amended portion of section 3(d) clearly sets up a second tier of qualifying standards for chemical substances/pharmaceutical products in order to leave the door open for true and genuine inventions but, at the same time, to check any attempt at repetitive patenting or extension of the patent term on spurious grounds” .Thus Supreme court clear the mist around patentability of new form of known substance where such form prove to be have improvement in efficacy. Here the efficacy as explained by the court should in the context of the pharmaceutical patenting be understood as “therapeutic efficacy”. Explaining the meaning of the term efficacy Supreme Court ruled that “Efficacy means “the ability to produce a desired or intended result”. Application of this in practice would clearly mandates that test of efficacy in the context of Section 3(d) would be different, depending upon the result the product under consideration is desired or intended to produce. Thus it would depend upon the function, utility or the purpose of the product under consideration. If we see its application on pure form of prostaglandins it would mean that in a claims relating to substance meant to cure a disease, the test of efficacy can only be “therapeutic efficacy”. If it is proved that isolated pure prostaglandin is better in efficacy as compared to prostaglandins naturally occurring in the fluids, it would perhaps qualify as patentable under the Indian Law.

Obviousness and substantially pure form

It not true that every substantially pure form of a natural product would have a free ride on patent grants. The product so claimed must also cross the obviousness threshold to pass the patent grant. Let’s take another example of substantially pure form US 6,500,829patent dispute In Spectrum Pharmaceuticals, Inc., v. Sandoz Inc., [Fed. Cir. Oct. 2, 2015]. The ’829 patent is directed to pharmaceutical compositions of substantially pure levoleucovorin. The Court in this case ruled that claims of a mixture comprising at least 92% of the (6S) isomer of leucovorin are obvious when both the 50/50 mixture of isomers and the pure (6S) isomer were known in the art. There was no evidence court observed to indicate that claimed mixture “possessed unexpected advantages over the prior art pure material” so as to overcome obviousness.” Another aspect which went against the patent was evidence which clearly demonstrated that purified (6S) leucovorin and a 50/50 mixture of isomers are clinically interchangeable. This case clearly demonstrates that possibility of getting a patent or defending it rests on proving its efficacy over the known product. Patent act in Indian context codified this thin line under section 3 (d) to keep obvious or clinically interchangeable products under non patentable subject matter to put a check on evergreening of a patent.

Recent trends – looking forward

In USA and even in other jurisdiction the scope of getting patent on product of nature has not changed substantially since the first pure form patent was granted. For example in May 2019 US district court in a pure form cannabinoids case denied Pure Hemp’s Early Motion for Partial Summary Judgment on the claims of UCANN's U.S. Patent No. 9,730,911 for "[a] liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is" a specified cannabinoid (CBD or THC or a combination). The court did not in fact deviated from precedent for purified natural products thus leaving enough room for grant of such patents. In Indian context if the product of nature substantially differs from the product which is result of handiwork of the inventor he may cross the 3(d) line directed to one of those patent-ineligible concepts such as pure form. Only requirement in India for such products would be that they are mandated to prove its efficacy over the known product. Therefore, in India purity per se is no guarantee that patent would be granted. However, the claim to a process to isolate a substance occurring in nature and making it available in pure form is patentable. Where the claims for isolation of product of nature or substance occurring in nature is characterised by its process or by structure it would also qualify as patent eligible subject matter. In such situation the claims may include patenting of product of nature per se. Does this mean that section 3 (c) limitations are merely to restrict the patenting of discoveries which are handiwork of nature? However, in absence of precedence subject matter eligibility would perhaps remain the core question on patentability of pure form. Though the Supreme Court decisions in Novartis did raise the hurdle bar higher to meet subject matter eligibility for new forms yet the more efficacious forms would continue to receive patents in India.

Originally published by Lexology

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions